


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
-2.62%
-0.92%
+1.09%
-11.46%
EXEL
Exelixis
$41.36
Strengths

Earnings are forecast to grow

Upgraded on attractively valued

Trading below its fair value
Technical Indicators

Crossed Below 200 DMA
EXEL Price Performance
$42.4 (-2.45%)
$40.37 (+2.45%)
$38.28 (+8.05%)
$34.2 (+20.94%)
Overall standing based on market and analyst consensus.
Hover over the category for more information
Earnings
Earnings

Above analyst estimates

Reported a strong earnings
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum
Activity
Activity
Future
Future

Earnings are forecast to grow

Trading below its fair value
![]()
EXEL Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
EXEL Street Sentiment is bullish and have positive views on the near-term outlook
EXEL has Low risk level

Average key support and resistance price levels
Recent Upgrades and Downgrades
BUY
Date
Action
Rating
Firm
Dec 18, 2025
Upgrade
Buy
Nov 07, 2025
Reiterate
Neutral
UBS
Nov 06, 2025
Reiterate
Buy
TD Cowen
Nov 06, 2025
Reiterate
Overweight
Morgan Stanley
Oct 28, 2025
Upgrade
Outperform
Leerink
RVMD
Revolution Medicines Inc.
96.95
-1.27%
BNTX
BioNTech
113.75
-2.59%
AMGN
Amgen
341.88
-0.31%
AGEN
Agenus
2.84
-5.02%
EXEL
Exelixis
41.36
-2.18%
BOX
Box
25.35
-0.55%
INBX
Inhibrx
76.27
+5.11%
PAGS
PagSeguro Digital
11.25
-6.25%
DQ
DAQO New Energy
24.72
-3.66%
What is EXEL current stock price?
What are EXEL stock strengths?
What is EXEL Risk Level?
What is EXEL market cap and volume?
What is EXEL current Stock IQ?
Should I buy EXEL stock right now?
Is EXEL a Strong Buy right now?
What does a 'Strong Buy' rating mean for EXEL?
What does a 'Strong Sell' rating mean for EXEL?
What factors influence EXEL's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-2.62%
-0.92%
+1.09%
-11.46%
EXEL
Exelixis
Current Price
$41.36
Linked to EXEL
RVMD
Revolution Medicines Inc.
96.95
-1.27%
BNTX
BioNTech
113.75
-2.59%
AMGN
Amgen
341.88
-0.31%
AGEN
Agenus
2.84
-5.02%
Recently Viewed
EXEL
Exelixis
41.36
-2.18%
BOX
Box
25.35
-0.55%
INBX
Inhibrx
76.27
+5.11%
PAGS
PagSeguro Digital
11.25
-6.25%
DQ
DAQO New Energy
24.72
-3.66%

EXEL Price Performance
$42.4 (-2.45%)
$40.37 (+2.45%)
$38.28 (+8.05%)
$34.2 (+20.94%)
EXEL Analysts Opinion
Overall standing per market and analyst expectations.
Hover over the category for more information
Earnings
Earnings

Above analyst estimates

Reported a strong earnings
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum
Activity
Activity
Future
Future

Earnings are forecast to grow

Trading below its fair value
![]()
EXEL Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
EXEL Street Sentiment is bullish and have positive views on the near-term outlook
EXEL has Low risk level

Average key support and resistance price levels
Overall Wall Street Rating
BUY
Dec 18, 2025
Upgrade
Buy
Nov 07, 2025
Reiterate
Neutral
UBS
Nov 06, 2025
Reiterate
Buy
TD Cowen
Nov 06, 2025
Reiterate
Overweight
Morgan Stanley
Oct 28, 2025
Upgrade
Outperform
Leerink
EXEL Stock IQ
Stock Insights
Strengths

Earnings are forecast to grow

Upgraded on attractively valued

Trading below its fair value
Technical Indicators

Crossed Below 200 DMA
EXEL Latest Analysis
EXEL Makes Notable Cross Below Critical Moving Average. In trading on Friday shares of Exelixis Inc (Symbol: EXEL) crossed below their 200 day moving average of $41.08 changing hands as low as $40.76 per share. Exelixis Inc shares are currently trading down about 2.7% on the day. The chart below shows the one year performance of
Fri Jan 30, 2026
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term. Wondering how to pick strong market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Tue Jan 27, 2026
Exelixis: High-Growth Oncology Name Trading At A Discount.
Thu Jan 22, 2026
Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term. The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Heres why you should take advantage.
Thu Jan 15, 2026
Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report?. Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Wed Jan 14, 2026
Exelixis Inc. (EXEL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript.
Tue Jan 13, 2026
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
EXEL Stock trends
EXEL Stock performance
EXEL Stock analysis
EXEL investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.